×
About 3,153 results

ALLMedicine™ Acid Phosphatase Center

Research & Reviews  1,175 results

Identification of acid phosphatase (ShACP) from the freshwater crab Sinopotamon henanen...
https://doi.org/10.1016/j.ecoenv.2023.114762
Ecotoxicology and Environmental Safety; Sang ZW, Bao MN et. al.

Mar 18th, 2023 - Acid phosphatase(ACP) is an important immune enzyme in crustacean humoral immunity. At present, the research on ACP mainly focuses on the biochemical properties of the enzyme, while few studies on gene expression. In this study, ShACP was cloned a...

Scutellaria polysaccharide mediates the immunity and antioxidant capacity of giant fres...
https://doi.org/10.1016/j.dci.2023.104678
Developmental and Comparative Immunology; Sun L, Lin F et. al.

Mar 13th, 2023 - The giant freshwater prawn (Macrobrachium rosenbergii) is a commercially valuable freshwater crustacean species that frequently appears a death affected by various diseases, resulting in substantial economic losses. Improving the survival rate of ...

The Effect of Spring Barley Fertilization on the Content of Polycyclic Aromatic Hydroca...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001663
International Journal of Environmental Research and Publi... Mackiewicz-Walec E, Krzebietke SJ et. al.

Mar 12th, 2023 - Soil-dwelling microorganisms play an important role in the environment by decomposing organic matter, degrading toxic compounds and participating in the nutrient cycle. The microbiological properties of soil are determined mainly by the soil pH, g...

Evaluation of heat-inactivated Limosilactobacillus fermentum CCFM1139 and its supernata...
https://doi.org/10.1039/d2fo02938c
Food & Function; Ye Y, Xu X et. al.

Mar 8th, 2023 - Periodontitis is a chronic inflammatory disease induced by subgingival microbial dysbiosis, characterised by inflammation of the soft tissues of the periodontium and progressive loss of alveolar bone. Limosilactobacillus fermentum CCFM1139 is a pr...

Phenolic acids-rich fraction from Ficus drupacea leaves for the prevention and treatmen...
https://doi.org/10.1007/s10787-023-01158-4
Inflammopharmacology Bakry SM, Naser AFA et. al.

Feb 26th, 2023 - Bioactivity-guided fractionation of F. drupacea Thunb. extract revealed that the water fraction (FDWF) increased pH of the artificial gastric juice from 1.2 to 5.67 ± 0.015. The gastroprotective effect of FDWF against ulcer induced by ethanol was ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  26 results

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
https://clinicaltrials.gov/ct2/show/NCT05735197

Feb 21st, 2023 - All patients have been recruited from the renal clinic of Nephrology and transplantation unit. The entire study will be conducted at Urology and Nephrology center in Mansoura University. Study design and sample size: • Sample size: Was calculated ...

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT05553639

Feb 3rd, 2023 - This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalat...

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
https://clinicaltrials.gov/ct2/show/NCT05704088

Jan 30th, 2023 - Study sitting: Nephrology and renal transplant unit at urology and nephrology center in Mansoura University. Study design and sample size: Randomized, controlled trial that will include 100 patients with Lupus nephritis (LN) with an estimated glom...

Denosumab Treatment in CKD Patients at High Risk of Fracture
https://clinicaltrials.gov/ct2/show/NCT05692297

Jan 25th, 2023 - Objective: To verify the efficacy and safety of denosumab in the prevention and treatment of CKD-MBD in CKD patients with high risk of fracture. Methods: A cohort of CKD patients with high risk of fracture was established and followed up for long ...

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02499835

Dec 1st, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety of pembrolizumab in combination with pTVG-HP (pTVG-HP plasmid DNA vaccine) in patients with castration-resistant, metastatic prostate cancer. II. To determine the 6-month progression-free survival and ...

see more →

News  57 results

The Orifices -- Where Most of Medicine's Money Is Made
https://www.medscape.com/viewarticle/983376

Nov 2nd, 2022 - Since antiquity, physicians have used their senses to study and try to understand human health and disease. Sight, sound, touch, smell, and taste. For much of history and for most physician-clinicians today, those five senses, when used well, are ...

Immunotherapeutics Aim for Larger Role in Prostate Cancer
https://www.onclive.com/view/immunotherapeutics-aim-for-larger-role-in-prostate-cancer

Jun 29th, 2022 - Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies. However, they have demonstrated relatively limited benefit in the treatment of patients with prostate cancer. I...

Renowned Prostate Cancer Experts Translate Research into Practice at the IPCC
https://www.onclive.com/view/ipcc_prostate_cancer

Mar 15th, 2022 - Click here to view as PDF. The Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) took place March 27 in New York, New York. ArcMesa Educators organized the event, which was open to urologists, radiologists, and medical oncologists. S...

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC
https://www.onclive.com/view/immune-correlates-may-indicate-responsiveness-to-ipilimumab-in-mcrpc

Oct 6th, 2021 - Sumit Subudhi, MD, PhD A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of...

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T
https://www.onclive.com/view/vogelzang-disputes-weak-guideline-rating-for-sipuleucel-t

Oct 6th, 2021 - Nicholas J. Vogelzang, MD In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the imp...

see more →